These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 7887641)

  • 41. [Steady state and disappearance of the metabolites of miproxifene phosphate in the treatment of breast cancer].
    Morimoto K; Abe O; Kinoshita H
    Gan To Kagaku Ryoho; 1998 Aug; 25(10):1565-73. PubMed ID: 9725050
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Novel intermittent GnRHa therapy for patients with endometriosis].
    Tanaka T; Umesaki N
    Nihon Rinsho; 2001 Jan; 59 Suppl 1():124-8. PubMed ID: 11235149
    [No Abstract]   [Full Text] [Related]  

  • 43. Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients.
    Boccardo F; Rubagotti A; Amoroso D; Agostara B; Amadori D; Gallo L; Iacobelli S; Massidda B; Mesiti M; Pacini P; Tomao S; Paganuzzi M; Marroni P
    Cancer Chemother Pharmacol; 1999; 43(6):461-6. PubMed ID: 10321505
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [First national Enantone Symposium. Progress in therapy of prostatic cancer. Multicenter study: long-term follow-up].
    Fornara P
    Urologe A; 1991 May; 30(3 Suppl):10-2. PubMed ID: 1746070
    [No Abstract]   [Full Text] [Related]  

  • 45. Leuprolide acetate depot plus high-dose raloxifene hydrochloride before and after surgery for recurrent vaginal aggressive angiomyxoma: a case report.
    Palomba S; Oppedisano R; Annunziata G; Zullo F; Amorosi A
    Gynecol Oncol; 2011 Oct; 123(1):172-3. PubMed ID: 21764109
    [No Abstract]   [Full Text] [Related]  

  • 46. [LH-RH analogues in metastatic breast cancer: first results].
    Terzoli E; Izzo F; Nisticò C; Lucatelli S; Ranuzzi M
    G Ital Oncol; 1988; 8(2):59-63. PubMed ID: 3065224
    [No Abstract]   [Full Text] [Related]  

  • 47. [Galenic innovation: Enantone monthly depot preparations].
    Hübner R
    Urologe A; 1991 May; 30(3 Suppl):7-8. PubMed ID: 1746074
    [No Abstract]   [Full Text] [Related]  

  • 48. Adverse effects of leuprolide acetate depot treatment.
    Friedman AJ; Juneau-Norcross M; Rein MS
    Fertil Steril; 1993 Feb; 59(2):448-50. PubMed ID: 8425646
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.
    Kurebayashi J; Shiba E; Toyama T; Matsumoto H; Okazaki M; Nomizu T; Ohtake T; Fujii T; Ohashi Y
    Breast Cancer; 2021 May; 28(3):684-697. PubMed ID: 33638810
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.
    Shiba E; Yamashita H; Kurebayashi J; Noguchi S; Iwase H; Ohashi Y; Sasai K; Fujimoto T
    Breast Cancer; 2016 May; 23(3):499-509. PubMed ID: 25655898
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)--outline of pre-clinical and clinical studies].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 2002 Sep; 29(9):1675-87. PubMed ID: 12355959
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Long-term clinical study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group].
    Taguchi T; Koyama H; Yayoi K; Wada T; Takatsuka Y; Sonoo H; Morimoto K; Tominaga T; Abe R; Enomoto K
    Gan To Kagaku Ryoho; 1995 Mar; 22(4):495-508. PubMed ID: 7887641
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [A dose-comparative study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group].
    Taguchi T; Koyama H; Yayoi K; Wada T; Takatsuka Y; Sonoo H; Morimoto K; Tominaga T; Abe R; Enomoto K
    Gan To Kagaku Ryoho; 1995 Mar; 22(4):477-94. PubMed ID: 7887640
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR].
    Niijima T; Aso Y; Akaza H; Fujita K; Fuse H; Hosaka M; Isurugi K; Kamidono S; Katayama T; Kawabe K
    Hinyokika Kiyo; 1990 Nov; 36(11):1343-60. PubMed ID: 2126912
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term clinical study on luteinising hormone-releasing hormone agonist depot formulation in the treatment of stage D prostatic cancer. The TAP-144-SR Study Group.
    Akaza H; Usami M; Koiso K; Kotake T; Aso Y; Niijima T
    Jpn J Clin Oncol; 1992 Jun; 22(3):177-84. PubMed ID: 1518166
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
    Koiso K; Akaza H; Naito S; Usami M; Tsukamoto T; Shimazaki J; Kotake T; Yamanaka H; Oohashi Y; Yoshinaka R; Onouchi H; Yokokawa K
    Hinyokika Kiyo; 2002 Dec; 48(12):781-95. PubMed ID: 12613016
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.